Comparison of the blood immune repertoire with clinical features in chronic lymphocytic leukemia patients treated with chemoimmunotherapy or ibrutinib.

ABSTRACT: Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of CD19⁺ CD5⁺ clonal B lymphocytes in the blood, bone marrow, and peripheral lymphoid organs. Treatment options for patients range from historical chemoimmunotherapy (CIT) to small molecule inhibitors targeting pro-survival pathways in leukemic B cells, such as the Bruton's tyrosine kinase inhibitor ibrutinib (IBR). Using biobanked blood samples obtained pre-therapy and at standard response evaluation timepoints, we performed an in-depth evaluation of the blood innate and adaptive immune compartments between pentostatin-based CIT and IBR and looked for correlations with clinical sequelae. CD4⁺ conventional T cells and CD8⁺ cytotoxic T cells responded similarly to CIT and IBR,

SUBMITTER: Welch BM 

PROVIDER: S-EPMC10725910 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature